Use of Flecainide for the Treatment of Atrial Fibrillation
Key result
Flecainide safely terminates and suppresses AF in patients without structural heart disease.
Why the study?
The use of flecainide for AF rhythm control is limited despite guideline recommendations and evidence of safety and efficacy in patients without structural heart disease.
Does flecainide improve the restoration and maintenance of normal sinus rhythm in patients with atrial fibrillation without structural heart disease?
Population
Patients with atrial fibrillation, particularly without structural heart disease
Comparison
Flecainide versus other antiarrhythmic drugs
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May support flecainide for AF rhythm control without SHD; leaves open updated RCTs to address underutilization.
Key Points
- To review the clinical efficacy, safety profile, and administration guidelines for flecainide in restoring and maintaining normal sinus rhythm in patients with atrial fibrillation.
- Narrative review synthesizing evidence from clinical trials and real-world studies evaluating flecainide for acute rhythm conversion and chronic rhythm maintenance in atrial fibrillation.
- Assessment of drug safety, tolerability, and proarrhythmia risks specifically across patient cohorts with and without underlying structural heart disease.
- Flecainide exhibits superior efficacy compared with alternative antiarrhythmic drugs for the acute termination of recent-onset atrial fibrillation.
- For the chronic suppression of paroxysmal and persistent atrial fibrillation, flecainide demonstrates moderate efficacy comparable to most antiarrhythmics, with the exception of amiodarone.
- Flecainide maintains a safe and well-tolerated profile in patients without structural heart disease, demonstrating that historical concerns regarding ventricular proarrhythmia are unfounded in this specific subgroup.
Structured PICO
Does flecainide improve the restoration and maintenance of normal sinus rhythm in patients with atrial fibrillation without structural heart disease?
P
Population
Patients with atrial fibrillation (AF), particularly those without structural heart disease
I
Intervention
Flecainide
C
Comparator
Other antiarrhythmic drugs (AADs)
O
Outcome
Restoration and maintenance of normal sinus rhythm (acute termination of recent onset AF and chronic suppression of paroxysmal and persistent AF)
Flecainide is a safe and effective first-line therapy for rhythm control in atrial fibrillation patients without structural heart disease, despite historical underutilization.
Cite This Study
Echt et al. (2020) conducted a review in Atrial fibrillation. Flecainide vs. Other antiarrhythmic drugs was evaluated. Flecainide is effective for the acute termination and chronic suppression of atrial fibrillation, and is safe and well-tolerated in patients without structural heart disease.